Featured Posts

Tuesday, February 5, 2019

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor

-FIH Study in EGFR Exon 20 Insertions Will Commence in 2019- TOKYO and CAMBRIDGE, Mass., Feb. 5, 2019 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. and Cullinan Oncology, LLC announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine ...

from PR Newswire: https://prn.to/2teBjVP

No comments:

Post a Comment